Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Autor: Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Elli EM; Fondazione IRCCS San Gerardo dei Tintori, divisione di ematologia e unità trapianto di midollo, Monza, Italy., Morsia E; Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy., Benevolo G; University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy., Tiribelli M; Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy., Beggiato E; Unit of Hematology, Department of Oncology, University of Torino, Torino, Italy., Bonifacio M; Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy., Farina M; Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Martino B; Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy., Caocci G; Ematologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy., Pugliese N; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy., Tieghi A; Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Crugnola M; Haematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Binotto G; Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy., Cavazzini F; Division of Hematology, University of Ferrara, Ferrara, Italy., Abruzzese E; Division of Hematology, Ospedale S. Eugenio, Roma, Italy., Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Isidori A; Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy., Bosi C; Division of Hematology, AUSL di Piacenza, Piacenza, Italy., Guglielmana V; Fondazione IRCCS San Gerardo dei Tintori, divisione di ematologia e unità trapianto di midollo, Monza, Italy., Venturi M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Dedola A; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Loffredo M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Fontana G; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Duminuco A; Postgraduate School of Hematology, University of Catania, Catania, Italy., Moioli A; Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy., Tosoni L; Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy., Scalzulli E; Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Lemoli RM; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Dipartimento di Medicina Interna e Specialità Mediche, Università di Genova, Genova, Italy., Cilloni D; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Bocchia M; Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy., Pane F; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy., Heidel FH; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany., Vianelli N; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Palumbo GA; Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia', University of Catania, Catania, Italy., Branzanti F; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Breccia M; Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.

Publikováno v: Cancer [Cancer] 2024 Dec 15; Vol. 130 (24), pp. 4257-4266. Date of Electronic Publication: 2024 Jul 30.

Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.

Autor: Breccia M; Department of Translational and Precision Medicine, Università Sapienza, Rome, Italy. Electronic address: breccia@bce.uniroma1.it., Cucci R; GIMEMA Data Center, Rome, Italy., Marsili G; GIMEMA Data Center, Rome, Italy., Castagnetti F; Department of Hematology, Istituto Seragnoli, Università di Bologna, Bologna, Italy., Galimberti S; Department of Hematology, Università di Pisa, Pisa, Italy., Izzo B; Department of Hematology, Università Federico II, Napoli, Italy., Sorà F; Department of Hematology, Università Cattolica, Roma, Italy., Soverini S; Department of Hematology, Istituto Seragnoli, Università di Bologna, Bologna, Italy., Messina M; GIMEMA Data Center, Rome, Italy., Piciocchi A; GIMEMA Data Center, Rome, Italy., Bonifacio M; Department of Hematology, Università di Verona, Verona, Italy., Cilloni D; Department of Hematology, Università di Torino, Torino, Italy., Iurlo A; Department of Hematology, Policlinico di Milano, Milano, Italy., Martinelli G; Department of Hematology, Istituto Seragnoli, Università di Bologna, Bologna, Italy., Rosti G; Department of Hematology, Istituto Amadori, Meldola, Italy., Stagno F; Department of Hematology, Università di Messina, Messina, Italy., Fazi P; GIMEMA Data Center, Rome, Italy., Vignetti M; GIMEMA Data Center, Rome, Italy., Pane F; Department of Hematology, Università Federico II, Napoli, Italy.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Sep 07. Date of Electronic Publication: 2024 Sep 07.

Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review.

Autor: Umurungi J; Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy., Ferrando F; Department of Medical Sciences, University of Turin, 10126 Turin, Italy., Cilloni D; Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy., Sivera P; Haematology and Cellular Therapies Unit, A.O. Ordine Mauriziano di Torino, 10128 Turin, Italy.

Publikováno v: Journal of clinical medicine [J Clin Med] 2024 Aug 12; Vol. 13 (16). Date of Electronic Publication: 2024 Aug 12.

Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).

Publikováno v: In Blood 23 September 2010 116(12):2196-2196

Pellicano F, Cilloni D, Helgason GV, Messa F, Panuzzo C, Arruga F, Bracco E, Allan E, Huntly BJ, Holyoake TL, Saglio G. FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells [published online ahead of print December 1, 2009]. Blood. doi 10.1182/blood-2009-06-226621

Autor: Tessa L. Holyoake

Publikováno v: Blood. 115:2983-2983

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a07c32602b1eb7ab47c136db77bee852
https://doi.org/10.1182/blood-2010-03-273375